局部应用贝伐单抗治疗穿透性角膜移植术后角膜新生血管化
Topical bevacizumab for corneal neovascularization after penetrating keratoplasty.
作者信息
Saxena Sandeep, Kishore Poonam, Pandey Sukant, Khattri Mohit, Kumar Dipak
机构信息
Department of Ophthalmology, CSM Medical University (Erstwhile King George's Medical University), Lucknow - India.
出版信息
Eur J Ophthalmol. 2009 Sep-Oct;19(5):870-2. doi: 10.1177/112067210901900530.
PURPOSE
To evaluate the efficacy of topical bevacizumab for corneal neovascularization in graft rejection.
METHODS
A 55-year-old man presented with corneal neovascularization and graft rejection 6 months following penetrating keratoplasty (triple procedure) in the left eye. His best-corrected visual acuity (BCVA) was counting fingers at 1 meter. He was administered topical bevacizumab (4 mg/4 mL) in a dose of one drop twice a day for 15 days. No adjunct therapy was given during bevacizumab administration.
RESULTS
After 1 month, his BCVA improved to 20/120. Corneal vascularization and stromal haze regressed. After 6 months, his BCVA improved to 20/60 with further regression in corneal vascularization and stromal haze. At 9-month follow-up, he maintained BCVA of 20/60.
CONCLUSIONS
Short-term topical bevacizumab therapy may potentially offer a safer and more effective alternative in treating graft rejection after penetrating keratoplasty.
目的
评估局部应用贝伐单抗治疗移植排斥反应中角膜新生血管的疗效。
方法
一名55岁男性在左眼穿透性角膜移植术（三联手术）后6个月出现角膜新生血管和移植排斥反应。他的最佳矫正视力（BCVA）为1米指数。给予他局部应用贝伐单抗（4毫克/4毫升），剂量为每天两次，每次一滴，共15天。在应用贝伐单抗期间未给予辅助治疗。
结果
1个月后，他的BCVA提高到20/120。角膜血管化和基质混浊消退。6个月后，他的BCVA提高到20/60，角膜血管化和基质混浊进一步消退。在9个月的随访中，他维持了20/60的BCVA。
结论
短期局部应用贝伐单抗治疗可能为穿透性角膜移植术后的移植排斥反应提供一种更安全、更有效的替代方法。
Zotero 插件